Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats

Abstract Context Fuzheng Huayu recipe (FZHY) combined with entecavir (ETV) is used to treat the cirrhosis caused by chronic hepatitis B (CHB) infection. Objective To investigate the effect of FZHY on ETV pharmacokinetics under different conditions. Materials and methods A model of liver fibrosis was created by intraperitoneal injection of dimethylnitrosamine (DMN; 10 μg/kg) for 4 weeks in Wistar rats. Ultra-high-performance liquid chromatography–tandem mass spectrometry was used to determine the blood concentration of ETV. Pharmacokinetic characteristics of ETV (0.9 mg/kg) were investigated after co-administration with FZHY (0.55 g/kg) at certain time intervals in normal and model rats. Results The analytical method for ETV was validated at 0.5–50 μg/L with a correlation coefficient = 0.9996, lower limit of quantitation of 0.5 μg/L and mean accuracy of 104.18 ± 9.46%. Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in C max to 27.38 μg/L, in AUC0– t from 323.84 to 236.67 μg/h/L, and a delay in T max from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in C max of 61.92%, delay in t 1/2 of 2.45 h and delay in T max of 2.92 h. The t 1/2e and V d/F of ETV were increased significantly to 8.01 h and 24.38 L/kg in the ETV-M group. Conclusions The effects of FZHY on ETV pharmacokinetics were diminished with an increase of interval time. The best time to administer both drugs is >2 h apart.

[1]  M. Buti,et al.  Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. , 2018, Journal of hepatology.

[2]  J. Pavlik,et al.  Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug–Drug Interactions , 2016, Front. Pharmacol..

[3]  Cheng-Hai Liu,et al.  Comparative pharmacokinetic and tissue distribution profiles of four major bioactive components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe. , 2015, Journal of pharmaceutical and biomedical analysis.

[4]  T. Yang,et al.  Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe. , 2015, Journal of ethnopharmacology.

[5]  M. A. Wouters,et al.  Potential role of glutathione in evolution of thiol-based redox signaling sites in proteins , 2015, Frontiers in Pharmacology.

[6]  S. Ahn,et al.  Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B , 2013, Clinical and molecular hepatology.

[7]  Tao Yang,et al.  Investigation of the absorbed and metabolized components of Danshen from Fuzheng Huayu recipe and study on the anti-hepatic fibrosis effects of these components. , 2013, Journal of ethnopharmacology.

[8]  Huijun Sun,et al.  OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  D. H. Sweet,et al.  Competitive inhibition of human organic anion transporters 1 (SLC22A6), 3 (SLC22A8) and 4 (SLC22A11) by major components of the medicinal herb Salvia miltiorrhiza (Danshen). , 2013, Drug metabolism and pharmacokinetics.

[10]  A. Davey,et al.  Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  Ying He,et al.  Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers , 2010, Arzneimittelforschung.

[12]  Yue Zhang,et al.  Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition. , 2010, Journal of ethnopharmacology.

[13]  Yi-Yang Hu,et al.  Effect of Fuzheng Huayu formula and its actions against liver fibrosis , 2009, Chinese medicine.

[14]  J. Pawlotsky EASL Clinical Practice Guidelines. , 2009, Journal of hepatology.

[15]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[16]  E. Palumbo New Drugs for Chronic Hepatitis B: A Review , 2008, American journal of therapeutics.

[17]  S. J. Matthews,et al.  Entecavir for the treatment of chronic hepatitis B virus infection. , 2006, Clinical therapeutics.

[18]  Xun Hu,et al.  Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein , 2006, Cancer Chemotherapy and Pharmacology.

[19]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[20]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.